AR095131A1 - COMBINED FORMULATION OF TWO ANTIVIRAL COMPOUNDS - Google Patents
COMBINED FORMULATION OF TWO ANTIVIRAL COMPOUNDSInfo
- Publication number
- AR095131A1 AR095131A1 ARP140100352A ARP140100352A AR095131A1 AR 095131 A1 AR095131 A1 AR 095131A1 AR P140100352 A ARP140100352 A AR P140100352A AR P140100352 A ARP140100352 A AR P140100352A AR 095131 A1 AR095131 A1 AR 095131A1
- Authority
- AR
- Argentina
- Prior art keywords
- antiviral compounds
- combined formulation
- iedipasvir
- effective amount
- formulated
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- VRTWBAAJJOHBQU-KMWAZVGDSA-N ledipasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N([C@@H](C1)C=2NC(=CN=2)C=2C=C3C(F)(F)C4=CC(=CC=C4C3=CC=2)C=2C=C3NC(=NC3=CC=2)[C@H]2N([C@@H]3CC[C@H]2C3)C(=O)[C@@H](NC(=O)OC)C(C)C)CC21CC2 VRTWBAAJJOHBQU-KMWAZVGDSA-N 0.000 abstract 1
- 229960002461 ledipasvir Drugs 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 abstract 1
- 229960002063 sofosbuvir Drugs 0.000 abstract 1
- 239000007962 solid dispersion Substances 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Composiciones farmacéuticas con una cantidad eficaz de ledipasvir sustancialmente amorfo y una cantidad eficaz de sofosbuvir sustancialmente cristalino. Reivindicación 2: La composición farmacéutica de la reivindicación 1, caracterizada porque el Iedipasvir se formula como una dispersión sólida que comprende Iedipasvir disperso dentro de una matriz de polímero formada por un polímero farmacéuticamente aceptable.Pharmaceutical compositions with an effective amount of substantially amorphous ledipasvir and an effective amount of substantially crystalline sofosbuvir. Claim 2: The pharmaceutical composition of claim 1, characterized in that the Iedipasvir is formulated as a solid dispersion comprising Iedipasvir dispersed within a polymer matrix formed by a pharmaceutically acceptable polymer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361759320P | 2013-01-31 | 2013-01-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR095131A1 true AR095131A1 (en) | 2015-09-30 |
Family
ID=56119010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140100352A AR095131A1 (en) | 2013-01-31 | 2014-01-31 | COMBINED FORMULATION OF TWO ANTIVIRAL COMPOUNDS |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR095131A1 (en) |
-
2014
- 2014-01-31 AR ARP140100352A patent/AR095131A1/en not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY35298A (en) | FORMULATION IN SOLID DISPERSION OF AN ANTIVIRAL COMPOUND | |
| PE20151778A1 (en) | COMBINED FORMULATION OF TWO ANTIVIRAL COMPOUNDS | |
| CL2016000882A1 (en) | Compositions of arni against component c5 of the complement and methods for its use (divisional sol. No. 2710-15). | |
| UY35300A (en) | FORMULATION OF COMBINATION OF TWO ANTIVIRAL COMPOUNDS | |
| CL2017000287A1 (en) | 2- (morpholin-4-yl) -1,7-naphthyridines. | |
| MX2015008627A (en) | Boronic acid derivatives and therapeutic uses thereof. | |
| MX2015008628A (en) | Boronic acid derivatives and therapeutic uses thereof. | |
| ECSP13012569A (en) | DEXMEDETOMIDINE PREMIX FORMULATION | |
| UY35040A (en) | PIRROLOPIRIMIDINILAMINO-BENZOTIAZOLONAS REPLACED | |
| AR095132A1 (en) | FORMULATION IN SOLID DISPERSION OF AN ANTIVIRAL COMPOUND | |
| MX378946B (en) | BINDER COMPOSITIONS AND METHODS FOR MANUFACTURING AND USING THE SAME. | |
| CO6741223A2 (en) | Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases | |
| PH12016500793A1 (en) | Turmeric extract containing soft pastilles | |
| BR112015011430A2 (en) | composition for immediate and prolonged release | |
| NI201600006A (en) | PYRAZOLO-PYRIDINAMINES SUBSTITUTED | |
| UY35848A (en) | TIENOPIRIMIDINS | |
| GT201500123A (en) | SOLID DISPERSION WITH IMPROVED SOLUBILITY THAT INCLUDES A TETRAZOL DERIVATIVE AS ACTIVE INGREDIENT | |
| CR20150555A (en) | NEW DERIVATIVES OF PIRROLO [2,3-D] PYRIMIDINE | |
| PE20151669A1 (en) | AZETIDINYLOXPHENYLPYRROLIDINE COMPOUNDS | |
| CL2015002466A1 (en) | Organic compound formulations | |
| CL2015001289A1 (en) | New derivatives of substituted 1,4-dithiine and its use as fungicides | |
| WO2014182789A3 (en) | Radiomitigating pharmaceutical formulations | |
| AR130558A2 (en) | PHARMACEUTICAL COMPOSITION INCLUDING LEDIPASVIR AND SOFOSBUVIR, PHARMACEUTICAL DOSAGE FORM AND TABLET INCLUDING IT | |
| AR095131A1 (en) | COMBINED FORMULATION OF TWO ANTIVIRAL COMPOUNDS | |
| BR112015014180A2 (en) | gel compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |